Organovo (NASDAQ:ONVO) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Organovo (NASDAQ:ONVO) in a research note published on Saturday. The firm issued a sell rating on the medical research company’s stock.

Organovo Stock Performance

Shares of NASDAQ:ONVO traded up $0.08 during midday trading on Friday, reaching $1.03. 1,110,523 shares of the company traded hands, compared to its average volume of 2,935,520. Organovo has a 12 month low of $0.89 and a 12 month high of $2.05. The firm’s fifty day moving average price is $1.04 and its two-hundred day moving average price is $1.11.

Organovo (NASDAQ:ONVO) last released its quarterly earnings data on Thursday, February 8th. The medical research company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.01. The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.08 million. Research analysts predict that Organovo will post -1.74 EPS for the current year.

About Organovo

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.